Navigation Links
Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Date:5/16/2008

peia's estimates of the market opportunities for PS433540, the implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS178990, a product candidate from its SARM program, Pharmacopeia's Phase 1 clinical studies with respect to PS178990, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS031291, a product candidate from its chemokine receptor CCR1 program, Pharmacopeia's estimates of the market opportunities for its other product candidates, including PS178990 and PS031291, Pharmacopeia's ability to raise additional capital, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's ability to successfully perform under its collaborations with Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Schering-Plough and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
3. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
7. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015 According ... Hybridization Market Study (2014-2019) by Type (DNA ISH, RNA ... By End User (Hospitals, Pharma & Biotech Companies, Research ... at $554.4 million 2014 and is estimated to reach ... during the forecast period, 2014 to 2019. ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v4wlnk/key_pharma_news ) ... Pharma News Issue" newsletter to their offering. ... burgeoning oncology pipeline and serves as a statement ... in 2015, with a large-scale potentially transformative acquisition ... Key Pharma News covers all major developments in ...
(Date:7/27/2015)... -- Cardica, Inc. (Nasdaq: CRDC ) today announced that it ... June 30, 2015, on Thursday, August 6, 2015, after the ... 4:30 p.m. Eastern Time to discuss the financial results and ... Conference Call Details To access the live conference call on ... please dial 877-703-6106 from the United States ...
Breaking Medicine Technology:Global In-Situ Hybridization Market to be Worth $681.0 Million by 2019 2Global In-Situ Hybridization Market to be Worth $681.0 Million by 2019 3Key Pharma News Issue - Gilead will make further oncology deals in 2015 2Key Pharma News Issue - Gilead will make further oncology deals in 2015 3Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 2
... , WALTHAM, Mass., Dec. 14 According ... technology market intelligence, increased use of safety devices for small-bore ... driver of the enteral feeding device markets in both the ... for Enteral Feeding Devices 2010 report finds that the ...
... Colo., Dec. 14 Manchester Pharmaceuticals, Inc.(TM) announced today ... On October 22, 2009, the US Food and Drug ... suffering from gallstones in whom surgery poses an unacceptable ... Chenodal prescriptions have started to be dispensed to patients ...
Cached Medicine Technology:Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3Manchester Announces Availability of Chenodal(TM) 2
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... The heroin ... country, reported WCNC on July 7th. The rate for heroin usage has ... has gone down considerably, and is a less expensive alternative for those with an ...
(Date:7/27/2015)... ... July 27, 2015 , ... In a piece ... personal side of plastic surgery and explained why people should not shy away from ... for the excesses of the few and celebrate it for the modern wonder that ...
(Date:7/27/2015)... Plains, NJ (PRWEB) , ... July 27, 2015 , ... ... tendon of an accomplished athlete. “The patient is high-end athlete, whose accomplishments include ... after 8 months of Achilles tendon pain, which was diagnosed as tendinitis. I ...
(Date:7/27/2015)... , ... July 27, 2015 , ... ... including emergency notification and mobile collaboration, announced today the ... user interface, language localization and other feature enhancements. , This software release gives ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... and in-depth research report. The report provides basic information such as calcium ... This report covers the global (US, Europe, Japan etc) industry analysis like ...
Breaking Medicine News(10 mins):Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 3Health News:Recent Op-Ed Defending Plastic Surgery Highlights the Personal Side of Cosmetic Procedures, says Beverly Hills Physicians 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3Health News:Send Word Now Announces Release of New User Interface for its Award-Winning Mass Notification Service 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3
... understanding of dopamine release from nerve cells, findings that ... treating Parkinson,s Disease. People with Parkinson,s Disease ... movement and, in extreme cases, a loss of physical ... of dopamine producing nerve cells in the brain. ...
... finds increase lowers chance of hospitalization or death ... with heart failure, high doses of the drug losartan, ... admission and death, a new study shows. , Though ... the study focused on whether dose level makes a ...
... ... expertise offers a winning combination to companies with large sales forces. , ... Chicago, IL (PRWEB) November 18, ... , knowledge and collaboration platform, and ELA Consulting Group , sales effectiveness and ...
... ... of resources to help community health officials make use of the company’s new mapping ... white paper and a free webinar, each demonstrate how Depiction can be used as ... ...
... A ... a new technique available at Houston weight loss surgery practice Texas Laparoscopic ... surgical treatment for morbid obesity. , ... (Vocus) November 18, 2009 -- Houston-based Texas Laparoscopic Consultants is a ...
... ... families learn five steps for creating joyful holidays and family celebrations. , ... (PRWEB) November 18, 2009 -- PAIRS Foundation is ... joyful holidays and family celebrations. , ,"Holidays can be a time of wonderful celebration, sharing ...
Cached Medicine News:Health News:Findings that should speed the development of drugs for Parkinson's disease 2Health News:Heart Failure Drug May Help More in Higher Doses 2Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 2Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 3Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 4Health News:Community Health Officials Can Improve Real Time H1N1 Information Sharing with New Resources from Depiction, Inc. 2Health News:Community Health Officials Can Improve Real Time H1N1 Information Sharing with New Resources from Depiction, Inc. 3Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 2Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 3Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 4Health News:Five Steps to Happy Family Gatherings at Holiday Time 2
The Nervous System Flash Cards product uses the time tested content and images from BryanEdwards.com and displays the necessary images to demonstrate the nervous system....
... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
Pocket Medicine's Cardiology Bundle includes the following 4 applications: Treatment Strategies in Cardiovascular Medicine, Treatment Strategies in Interventional Cardiology, Treatment Strategies in ...
Medicine Products: